Croissy-Beaubourg and Montpellier, 8 July 2014 - THERADIAG (ISIN: FR0004197747, Ticker: ALTER, PEA-PME eligible), a company specializing in in-vitro diagnostics and theranostics, today announces that its Lisa-Tracker range has been further expanded, with an 8th test receiving CE marking in oncology.
With the monitoring of the drug and of the anti-drug antibodies, this new test could optimize the treatment of patients on Avastin® (bevacizumab molecule). Avastin® is the only anti-angiogenic 1 therapy available for treating patients with advanced breast, colon, lung, kidney or ovarian cancer, which are responsible for more than 2.5 million deaths every year.
This kit, developed by Theradiag, is the Lisa-Tracker range's second test in oncology and will soon be marketed worldwide. It meets a major need from practitioners, with more than a million patients currently being treated with Avastin®. In 2013, sales of this drug totaled approximately 6.7 billion dollars (+8% compared with 2012). Furthermore, a vast program of more than 500 clinical trials is also currently underway and is looking into the possible use of Avastin® in around fifty additional types of tumor.

Michel Finance, CEO of THERADIAG, comments: "This 8th CE marked test is further proof of our commitment and our expertise in the development of the Lisa-Tracker range and our activity in theranostics. It enables us to expand our range and our activity to oncology. Further developments are ongoing, and will result in additional CE markings in 2014."

Capitalizing on its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag notably markets the Lisa-Tracker range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. With its subsidiary Prestizia, Theradiag is developing new biomarkers based on microRNAs for the diagnosis and monitoring of HIV/AIDS and rectal cancer. Theradiag is thus participating in the development of "customized treatment", which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. The Company is based in Marne-la-
Vallée, near Paris, and in Montpellier, and has over 60 employees.

1 Anti-angiogenic treatment: the use of drugs to inhibit angiogenesis, i.e. the production of blood vessels that irrigate cancerous tumors. The tumors, thus starved of blood, gradually disappear.

1/2

Investor Relations

Phone: +33 1 64 62 10 12

ntrepo@theradiag.com

NewCap.

Financial communications/

investor relations Valentine Brouchot / Pierre Laurent

Phone: +33 1 44 71 94 94 theradiag@newcap.fr

Press

2/2

distributed by